Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Cryan J et al. | FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity. | 1991 | Biochem. Biophys. Res. Commun. | pmid:1719972 |
Ryu S and Yasunami Y | Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. | 1991 | Transplant. Proc. | pmid:1703710 |
Karlsson H et al. | The immunosuppressive agent FK506 inhibits in vitro expression of membrane-bound and soluble interleukin-2 receptors on resting but not on activated human lymphocytes. | 1991 | Immunol. Lett. | pmid:1720417 |
Alejandro R et al. | Combined liver-islet allotransplantation in man under FK 506. | 1991 | Transplant. Proc. | pmid:1703712 |
FK-506 shows similar graft survival rate to cyclosporine but fewer side effects: Pitt transplant team. | 1991 | Nephrol News Issues | pmid:1720511 | |
Ito T et al. | The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. | 1991 | Transplant. Proc. | pmid:1703716 |
The discovery of FK-506 and U.S. development. | 1991 | Nephrol News Issues | pmid:1720512 | |
Zheng B et al. | Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. | 1991 | Transplant. Proc. | pmid:1703717 |
Christians U et al. | Interactions of FK 506 and cyclosporine metabolism. | 1991 | Transplant. Proc. | pmid:1721280 |
Wu YM et al. | Interaction between FK 506 and cyclosporine in dogs. | 1991 | Transplant. Proc. | pmid:1721281 |
Habucky K et al. | The pharmacodynamics of pentobarbital following FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721282 |
Farghali H et al. | Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. | 1991 | Transplant. Proc. | pmid:1721283 |
Wang SC et al. | FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. | 1991 | Transplant. Proc. | pmid:1721312 |
Woo J et al. | Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. | 1991 | Transplant. Proc. | pmid:1721313 |
McCarthy SA et al. | Effects of FK 506 and cyclosporine on T-cell tolerance: inhibition of a "protective" mechanism that regulates activation-induced apoptosis in developing thymocytes. | 1991 | Transplant. Proc. | pmid:1721314 |
Zeevi A et al. | Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721315 |
Mieles LA et al. | Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. | 1991 | Transplant. Proc. | pmid:1721344 |
Nakazato P et al. | Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. | 1991 | Transplant. Proc. | pmid:1721345 |
Nakamura K et al. | The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. | 1991 | Transplant. Proc. | pmid:1721346 |
Jain AB et al. | Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. | 1991 | Transplant. Proc. | pmid:1721347 |
Morris SM et al. | Disruption of renal function and gene expression by FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721375 |
Lagodziński Z et al. | Effect of FK 506 on B-cell responses. | 1991 | Transplant. Proc. | pmid:1703359 |
Lieberman KV et al. | FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). | 1991 | Transplant. Proc. | pmid:1721376 |
Demetris AJ et al. | Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. | 1991 | Transplant. Proc. | pmid:1703360 |
Ueda D et al. | Influence of FK 506 on renal blood flow. | 1991 | Transplant. Proc. | pmid:1721377 |
Thomson AW et al. | The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. | 1991 | Transplant. Proc. | pmid:1703361 |
Perico N et al. | FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. | 1991 | Transplant. Proc. | pmid:1721378 |
Mieles L et al. | Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. | 1991 | Transplant. Proc. | pmid:1703362 |
Warty V et al. | Distribution of FK 506 in plasma lipoproteins in transplant patients. | 1991 | Transplant. Proc. | pmid:1703363 |
Shinozuka H et al. | Effect of FK 506 on experimental liver carcinogenesis. | 1991 | Transplant. Proc. | pmid:1721407 |
Pelekanou V et al. | FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. | 1991 | Transplant. Proc. | pmid:1721408 |
Tai J et al. | In vivo and in vitro effect of FK 506 on rat Leydig cell function. | 1991 | Transplant. Proc. | pmid:1721409 |
Ricordi C et al. | Human islet allotransplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721410 |
Steinmann B et al. | Mechanism of action of FK 506 and cyclosporin. | 1991 | Lancet | pmid:1704088 |
Jiang H et al. | Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. | 1991 | Transplant. Proc. | pmid:1721439 |
Sato K et al. | Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. | 1991 | Transplant. Proc. | pmid:1721440 |
Katayama Y et al. | Immunosuppressive effects of FK 506 in rat lung transplantation. | 1991 | Transplant. Proc. | pmid:1721441 |
Yokomise H et al. | Immunosuppressive effects of FK 506 in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721442 |
Metcalfe S and Milner J | Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. | 1991 | Transplantation | pmid:1710844 |
Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
Neuberger J | FK 506--a promise of good things to come? | 1991 | Hepatology | pmid:1711005 |
Halloran PF and Madrenas J | The mechanism of action of cyclosporine: a perspective for the 90's. | 1991 | Clin. Biochem. | pmid:1711939 |
Starzl TE et al. | [Clinical experience with FK 506]. | 1991 | Presse Med | pmid:1722311 |
Granelli-Piperno A and McHugh P | Characterization of a protein that regulates the DNA-binding activity of NF-AT, the nuclear factor of activated T cells. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1722332 |
Nelson PA et al. | cDNA encoding murine FK506-binding protein (FKBP): nucleotide and deduced amino acid sequence. | 1991 | Gene | pmid:1722474 |
Chen MF et al. | The influence of FK-506 on the thymus and spleen in normal C3H/He mice: flow cytometric analysis of lymphocyte subpopulations. | 1991 | Immunol. Lett. | pmid:1722778 |
Christians U et al. | Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. | 1991 | Clin. Biochem. | pmid:1714802 |
Turka LA and Thompson CB | Structure-function relationship of immunosuppressive drugs: a cautionary tale. | 1991 | Hepatology | pmid:1714876 |
Brizuela L et al. | Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. | 1991 | Mol. Cell. Biol. | pmid:1715022 |
Heitman J et al. | Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. | 1991 | Science | pmid:1715094 |